Paul Burroughs, Director of Communications, (418) 652-8525 ext. 406, [email protected] CNW Group 2015
Aeterna Zentaris Announces Amendment to Series B Warrants
View original source (CNW)COSCIENS Biopharma Inc. on 6ix
Earlier from COSCIENS Biopharma
- Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
- Aeterna Zentaris Reports Second Quarter Financial and Operating Results
- Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October
- Aeterna Zentaris to Announce Second Quarter 2015 Financial and Operating Results on August 13, 2015
- Aeterna Zentaris to Present at Upcoming Canaccord Genuity 35th Annual Global Growth Conference in Boston
Later from COSCIENS Biopharma
- Aeterna Zentaris Announces Dismissal of Class Action Lawsuit
- Aeterna Zentaris Announces TSX Approval of Series B Warrant Amendment
- Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer
- Aeterna Zentaris Announces Restructuring of Finance & Accounting Operations and Closure of Quebec City Office
- Aeterna Zentaris: Data and Safety Monitoring Board Recommends Continuation of ZoptEC Phase 3 Trial in Advanced Endometrial Cancer
Follow COSCIENS Biopharma into a list and get an email when it puts out news.
Follow COSCIENS Biopharma